---
company: ATOSSA THERAPEUTICS, INC.
ticker: ATOS
form: 8-K
filed: 2026-11-10
accepted: 2026-11-10T13:15:13+00:00
accession: 0001193125-26-454486
source: https://www.sec.gov/Archives/edgar/data/1488039/000119312526454486/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1488039/000119312526454468/
---

# Atossa Therapeutics (ATOS) Q3 2026 earnings

## Header

- Company: Atossa Therapeutics, Inc.
- Reported: 2026-11-10 08:15 BMO ET
- Source: 8-K only — accession 0001193125-26-454486, Item 2.02 + Exhibit 99.1
- Verdict: Operating expenses declined sequentially and year-over-year, and the company secured a CVR agreement tied to a potential PRV monetization.

## Headline numbers

not stated in the 8-K

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $5.9M (-36.3% YoY)
- One-offs in the quarter: Other income (expense), net $0.1M; Other income (expense), net $0.1M (9M YoY)
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Cash and cash equivalents | $20.6M | $26.1M | $41.3M | -21.4% |
| Total assets | $26.4M | $32.3M | $47.6M | -18.2% |
| Total stockholders' equity | $21.7M | $26.8M | $39.4M | -19.0% |
| Weighted average shares outstanding | 9.99M | 8.91M | 8.62M | +12.1% |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| PRV net proceeds | Up to $50M | — | — |
| PRV share to CVR holders | 25% | — | — |
| IND clearance | Early 2027 | — | — |
| EVANGELINE topline data | Q2 2027 | — | — |

## What drove it

- Revenue story: No revenue reported.
- EPS story: Net loss per share widened year-over-year and sequentially due to higher operating expenses and increased share count.
- One-off check: Other income (expense), net $0.1M (9M YoY) and $0.1M (QoQ)

## The good

- Operating expenses decreased $3.4M YoY
- CVR agreement for 25% of PRV proceeds (up to $50M)

## The bad

- Net loss per share widened YoY and QoQ
- Cash balance decreased $5.5M QoQ
- Weighted average shares outstanding increased 12.1% YoY

## The ugly

- none

## Open questions

- The filing does not state the specific amount of the upfront proceeds from the CVR agreement.
- The filing does not provide a reconciliation of GAAP net loss to adjusted net loss.

## Full release

### Atossa Therapeutics (ATOS) earnings release, November 10, 2026

Atossa Therapeutics, Inc. (ATOS) · Form 8-K, Item 2.02 · Filed 2026-11-10 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1488039/000119312526454486/)

Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

SEATTLE, WASHINGTON, November 10, 2026 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results for the third quarter ended September 30, 2026 and provided an update on recent corporate developments.

“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs,” stated

Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer.

“Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027. In December 2026, presentations at the San Antonio Breast Cancer Symposium will include Karisma follow-up results and selected data from the ongoing I-SPY2 study evaluating (Z)-endoxifen in combination with other therapies.”

Third Quarter 2026 & Recent Highlights

• Stapled Contingent Value Rights (CVR) Agreement o

On October 8, 2026, the Company entered into a Stapled Contingent Value Rights Agreement (the CVR Agreement), and the Board of Directors (the Board) declared a dividend of one CVR for each share of Atossa common stock outstanding as of October 19, 2026 and issued thereafter. The CVRs remain attached to the underlying shares and will not trade separately unless the Board elects to detach them. o

CVR holders will be entitled, in the aggregate, to 25% of the net proceeds from the sale or other monetization of the first qualifying U.S. Food and Drug Administration (FDA) priority review voucher (PRV) awarded to Atossa, subject to a maximum aggregate payment of $50 million. o

No PRV has been awarded to the Company, and there can be no assurance that Atossa will receive or monetize a PRV or that any payment will ultimately be made under the CVR Agreement.

• CFO Attendance at Global Genes RARE Drug Development Symposium o

Mark Daniel, Atossa’s Chief Financial Officer, attended the Global Genes RARE Drug Development Symposium, held September 9–11, 2026, in Boston, Massachusetts. The symposium brought together patient advocates, researchers and biopharmaceutical industry leaders to explore research strategies, clinical trial readiness and collaboration in rare disease drug development. Atossa’s attendance supported its efforts to understand patient community priorities and explore approaches to advancing its rare disease development programs.

• CEO Attendance at NORD Rare Diseases and Orphan Products Breakthrough Summit o

Steven C. Quay, M.D., Ph.D., Atossa’s Chairman, President and Chief Executive Officer, attended the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, held October 25–27, 2026, in Washington, D.C. The Summit brought together patient advocates, researchers, industry leaders and policymakers to discuss advances in rare disease research, drug development, patient engagement and access to treatments. Atossa’s attendance supported its continued engagement with the rare disease community as the Company advances its (Z)-endoxifen programs in Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS).

Anticipated Milestones o

The Company anticipates Investigational New Drug (IND) application clearance from the FDA for (Z)-endoxifen in MAS and DMD by early 2027, with initiation of Phase 2 clinical trials expected in 2027. o

The Karisma trial was completed and the results finalized in the clinical study report. The Company is presenting these data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026, and will publicize the findings thereafter. o

The Company anticipates topline data from the Phase 2 EVANGELINE study of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2- breast cancer in the second quarter of 2027. Enrollment for the study was completed during the second quarter of 2026. o

Enrollment in the (Z)-endoxifen plus elagolix and (Z)-endoxifen plus abemaciclib arms of the Phase 2 I-SPY2 study is complete, and select data will be presented at SABCS in December 2026.

Financial Results for the Third Quarter Ended September 30, 2026

Operating Expenses.

Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, respectively, which represented a decrease of $3.4 million and $1.2 million from total operating expenses for the three and nine months ended September 30, 2025, which were $9.3 million and $25.7 million, respectively. Factors contributing to the changes in operating expenses during the three and nine months ended September 30, 2026, are explained below.

Research & Development (R&D) Expenses.

The following table provides a breakdown of major categories within R&D expenses for the three and nine months ended September 30, 2026 and 2025, together with the dollar change and percentage change in those categories (dollars in thousands):

As (Z)-endoxifen is our only product candidate for which we currently incur R&D expenses, we have not further disaggregated R&D expenses by product candidate.

• ... (truncated)or which enrollment was largely completed during the first nine months of 2026.

• The increase in R&D compensation expense of $0.2 million for the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025, was due primarily to increases in non-cash stock-based compensation expense.

• The decrease in R&D professional fees and other of $0.2 million and $0.7 million for the three and nine months ended September 30, 2026, respectively, compared to the three and nine months ended September 30, 2025, was due primarily to lower regulatory consulting fees related to our (Z)-endoxifen programs during the current year periods.

General and Administrative (G&A) Expenses.

The following table provides a breakdown of major categories within G&A expenses for the three and nine months ended September 30, 2026 and 2025, together with the dollar change and percentage change in those categories (dollars in thousands):

• The decrease in G&A compensation expenses of $0.3 million and $0.8 million for the three and nine months ended September 30, 2026, respectively, compared to the three and nine months ended September 30, 2025, was due primarily to a decrease in headcount in the current year periods compared to the same periods in the prior year.

• The decrease in G&A professional fees and other of $1.0 million for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, was due primarily to a decrease in legal fees of $0.8 million related to the resolution of patent litigation matters during the first half of 2026. The increase in G&A professional fees and other of $1.5 million for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025, was due primarily to higher spend on patent litigation matters during the first half of 2026, which have now been settled, and to a lesser extent, higher legal fees associated with management of our intellectual property portfolio and general legal costs related to SEC compliance and other stock administration matters incurred during the current year period.

Interest Income.

Interest income was $0.2 million and $0.7 million for the three and nine months ended September 30, 2026, respectively, and decreased $0.4 million and $1.2 million compared to the three and nine months ended September 30, 2025, respectively. The decrease was due primarily to lower average cash balances invested in our money market account during the current year periods relative to the same periods in the prior year.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company’s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings.

(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-endoxifen is not approved for any indication.

Atossa has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for (Z)-endoxifen for the treatment of DMD, as well as Rare Pediatric Disease (RPD) designation for (Z)-endoxifen for the treatment of both DMD and MAS. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher (PRV), which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. In the last 18–24 months, disclosed PRV sales have ranged from $100–$220 million.

Atossa’s (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide.

More information is available at https://atossatherapeutics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, our full year 2026 outlook; our expectations regarding the Company’s development and regulatory strategy and related milestones, including the timing of data; the potential indications that the Company may pursue for (Z)-endoxifen; the potential role of (Z)-endoxifen and (Z)-endoxifen-related compounds in endocrine therapies; the potential for (Z)-endoxifen to receive regulatory approval to commence clinical trials for DMD and MAS and the timing thereof; the Company's progress across its pipeline and potential commercialization; the strength of the Company's patent portfolio; the Company’s potential eligibility for, the value of, and the Company's ability to monetize a Rare Pediatric Disease PRV; potential payments under the CVR Agreement; and the potential market and growth opportunities for the Company. Words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.... (truncated)ing, completion and results of our preclinical studies, clinical trials, and research and development programs; the potential clinical significance of preclinical data and the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to receive orphan-drug exclusivity for (Z)-endoxifen for MAS; our ability to receive a PRV from the FDA; changes to, or the expiration of, the Rare Pediatric Disease PRV program; our ability to monetize any PRV we may receive and our expectations around any PRV’s potential future value; the number of outstanding CVRs, our ability to make a payment to CVR holders, and the expected timing of such payment, if any; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa’s filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

The market value of a PRV is variable and subject to a number of factors beyond our control and reported past PRV sale amounts are not necessarily indicative of PRV sale amounts in the future.

Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.

Investor and Media Contacts

Investors: WaterSeid Partners, Inc. — ATOS@waterseid.com

Media: Elev8 New Media — atossa@elev8newmedia.com

ATOSSA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED B

ALANCE SHEETS

(amounts in thousands, except share and per share data)

(Unaudited)

ATOSSA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STAT

EMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

(Unaudited)

#### Financial statements

##### Income Statement (For the Three Months Ended September 30, — (Unaudited))

| | For the Three Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Operating expenses** | | | | |
| Research and development | 3,378 | 5,370 | 13,054 | 15,029 |
| General and administrative | 2,521 | 3,881 | 11,409 | 10,676 |
| Total operating expenses | 5,899 | 9,251 | 24,463 | 25,705 |
| Operating loss | -5,899 | -9,251 | -24,463 | -25,705 |
| Interest income | 209 | 570 | 745 | 1,935 |
| Other income (expense), net | 52 | -11 |  | -63 |
| Loss before income taxes | -5,638 | -8,692 | -23,718 | -23,833 |
| Net loss | -5,638 | -8,692 | -23,718 | -23,833 |
| Net loss per share of common stock - basic and diluted | -0.56 | -1.01 | -2.58 | -2.76 |
| Weighted average shares outstanding used to compute net loss per share - basic and diluted | 9,990,226 | 8,622,289 | 9,178,686 | 8,622,289 |

##### Balance Sheet (September 30, 2026 — (Unaudited))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **Current assets** | | |
| Cash and cash equivalents | 20,574 | 41,299 |
| Restricted cash | 110 | 110 |
| Prepaid materials | 3,014 | 3,081 |
| Prepaid expenses and other current assets | 1,483 | 1,128 |
| Total current assets | 25,181 | 45,618 |
| Other assets | 1,267 | 1,990 |
| Total assets | 26,448 | 47,608 |
| **Current liabilities** | | |
| Accounts payable | 1,501 | 4,293 |
| Accrued expenses | 1,296 | 1,307 |
| Payroll liabilities | 1,167 | 1,558 |
| Other current liabilities | 745 | 1,097 |
| Total current liabilities | 4,709 | 8,255 |
| Total liabilities | 4,709 | 8,255 |
| **Stockholders' equity** | | |
| Common stock - $0.18 par value; 350,000,000 shares authorized; 9,979,298 and 8,611,361 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 1,796 | 1,550 |
| Additional paid-in capital | 291,698 | 285,840 |
| Treasury stock, at cost; 88,003 shares of common stock at September 30, 2026 and December 31, 2025 | -1,475 | -1,475 |
| Accumulated deficit | -270,280 | -246,562 |
| Total stockholders' equity | 21,739 | 39,353 |
| Total liabilities and stockholders' equity | 26,448 | 47,608 |

##### Cash Flow (From the 10-Q · For the Nine Months Ended September 30, — (Unaudited) (in thousands))

| | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **CASH FLOWS FROM OPERATING ACTIVITIES** | | |
| Net loss | -23,718 | -23,833 |
| **Adjustments to reconcile net loss to net cash used in operating activities** | | |
| Stock-based compensation | 2,084 | 2,143 |
| Depreciation | 12 | 12 |
| **Changes in operating assets and liabilities:** | | |
| Prepaid materials | 67 | -1,045 |
| Prepaid expenses and other current assets | -355 | 585 |
| Other assets | 711 | -339 |
| Accounts payable | -2,792 | 2,853 |
| Accrued expenses | -11 | 1,070 |
| Payroll liabilities | -391 | -737 |
| Other current liabilities | -352 | 68 |
| Net cash used in operating activities | -24,745 | -19,223 |
| **CASH FLOWS FROM INVESTING ACTIVITIES** | | |
| Purchases of property and equipment |  | -16 |
| Net cash used in investing activities |  | -16 |
| **CASH FLOWS FROM FINANCING ACTIVITIES** | | |
| Proceeds from issuance of common stock and warrants | 4,500 |  |
| Offering costs for common stock and warrant issuance | -501 |  |
| Proceeds from issuance of common stock under the ATM program, net of issuance costs | 21 |  |
| Net cash provided by financing activities | 4,020 |  |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | -20,725 | -19,239 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE | 41,409 | 71,194 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE | 20,684 | 51,955 |
| **RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH** | | |
| Cash and cash equivalents | 20,574 | 51,845 |
| Restricted cash | 110 | 110 |
| Total cash, cash equivalents and restricted cash | 20,684 | 51,955 |
